Retraction: Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.

Autor: Sampson VB; Cancer Therapeutics Laboratory, Nemours Center for Cancer and Blood Disorders, Nemours/A.I. duPont Hospital for Children, Wilmington, DE, USA., Vetter NS; Cancer Therapeutics Laboratory, Nemours Center for Cancer and Blood Disorders, Nemours/A.I. duPont Hospital for Children, Wilmington, DE, USA., Zhang W; Department of Pediatrics - Hematology and Oncology, The Children's Hospital at Montefiore, The Albert Einstein College of Medicine, Bronx, NY, USA., Patil PU; Nemours Center for Childhood Cancer Research, Alfred I. duPont Hospital for Children, Wilmington, DE, USA., Mason RW; Nemours Center for Childhood Cancer Research, Alfred I. duPont Hospital for Children, Wilmington, DE, USA., George E; Department of Biological Sciences, University of Delaware, Newark, DE, USA., Gorlick R; Department of Pediatrics - Hematology and Oncology, The Children's Hospital at Montefiore, The Albert Einstein College of Medicine, Bronx, NY, USA., Kolb EA; Cancer Therapeutics Laboratory, Nemours Center for Cancer and Blood Disorders, Nemours/A.I. duPont Hospital for Children, Wilmington, DE, USA.
Jazyk: angličtina
Zdroj: Oncotarget [Oncotarget] 2024 Oct 11; Vol. 15, pp. 725. Date of Electronic Publication: 2024 Oct 11.
DOI: 10.18632/oncotarget.28663
Databáze: MEDLINE